Gestational choriocarcinoma.

Area of Science:

• Gynecologic Oncology
• Medical Oncology
• Immunotherapy

Background:

• Gestational choriocarcinoma represents 5% of gestational trophoblastic neoplasms, occurring after various pregnancy types.
• The FIGO scoring system stratifies risk into low (0-6) and high (≥7), guiding treatment with single-agent or multi-agent chemotherapy.
• While chemotherapy offers high cure rates and fertility preservation for localized disease, multi-drug resistance remains a challenge in a small subset of patients.

Approach:

• This review by the Rare Tumor Working Group and European Organization for Research and Treatment of Cancer evaluates current management strategies for gestational choriocarcinoma.
• It examines the efficacy of chemotherapy and explores emerging therapeutic avenues, including immunotherapy.
• The review analyzes data on treatment responses to immunotherapy and novel combination therapies.

Key Points:

• Chemotherapy is the primary treatment, with high success rates, but <5% face multi-drug resistance.
• Immunotherapy demonstrates a high treatment response rate (50-70%) in limited data sets.
• Novel combinations of immune checkpoint inhibitors with targeted therapies, such as VEGFR-2 inhibitors, are under investigation.

Conclusions:

• PD-L1 inhibitors present a significant opportunity for chemo-resistant gestational choriocarcinoma, potentially replacing or reducing chemotherapy toxicity.
• Further research into immunotherapy combinations is crucial for improving outcomes in refractory cases.
• The review highlights the need for novel approaches to overcome chemo-resistance and enhance patient management.